
    
      OUTLINE:

      Patients receive rituximab intravenously (IV) on day 1, polatuzumab vedotin IV on day 1,
      prednisone orally (PO) twice daily (BID) on days 1-5, etoposide IV on days 1-4, doxorubicin
      IV on days 1-4, and cyclophosphamide IV on day 5. Patients also receive filgrastim
      subcutaneously (SC) 24-72 hours after the last dose of each treatment cycle. Treatment
      repeats every 21 days for up to 6 cycles in the absence of disease progression or
      unacceptable toxicity.

      After the completion of study treatment, patients are followed periodically for up to 5
      years.
    
  